iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time. This virtual presentation will be broadcasted live and archived on the iBio website under the 'News & Events' section.
iBio is known for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals, including treatments for cancers and infectious diseases.
Details
News Market Reaction – IBIO
The recorded move for IBIO in the trading session of this news was +1.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its Chairman & CEO, Tom Isett, will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.
The presentation will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, antigens, and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.